See What HealthDay Can Do For You
Contact Us

Scaled-Up Drug Treatment Could Prevent Deaths

Annual cost of intervention for cardiovascular disease averages to $1 per person

WEDNESDAY, Dec. 5 (HealthDay News) -- Scaling up treatment of individuals at high risk for cardiovascular disease with an evidenced-based, multidrug regimen would reduce deaths from cardiovascular disease in 23 countries by almost 18 million over a decade, at an average annual cost of only about $1 per person, according to an article published online Dec. 5 in The Lancet.

Stephen S. Lim, Ph.D., of the University of Washington in Seattle, and colleagues conducted a cost-benefit analysis of treating individuals at high risk for cardiovascular disease with an evidenced-based multidrug regimen (a statin, aspirin, and two antihypertensive medications) in 23 low- and middle-income countries. The researchers' analysis was limited to individuals who were already accessing the health care system.

A projected 17.9 million deaths over a 10-year period could be averted by this scaled-up treatment, 56 percent of which would be in individuals younger than 70 years. The projected 10-year cost of this intervention would be $47 billion, which corresponds to an average annual cost of $1.08 per person, ranging from $0.43 to $0.90 in low-income countries to $0.54 to $2.93 in middle-income countries.

"This intervention alone could avert almost a fifth of deaths from cardiovascular disease, which amounts to three-quarters of the global goal of an additional 2 percent yearly reduction in chronic disease death rates in these countries," the authors report.

Abstract
Full Text (subscription or payment may be required)

Physician's Briefing

HealthDay

HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.